TheraRadar
Home/Indications/Lower Respiratory Tract Infection

Lower Respiratory Tract Infection

0 original drugs
0
Novel Drugs
11
Reformulations
0
Active Trials
1
Drug Targets

Lower Respiratory Tract Infection has 0 FDA-approved novel treatments across 1 drug target. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Phase 3 Readouts Pro

8 active Phase 3 trials with confidence-graded completion dates.

Full calendar →
Q4 2026
Pirfenidone Capsules (400 mg)
Beijing Continent Pharmaceutical Co, Ltd.
Estimated · fresh NCT07388680
Q4 2026
Meropenem and Pralurbactam
Qilu Pharmaceutical Co., Ltd.
Estimated · aging NCT07089186
Q4 2027
BV100 (300 mg)
BioVersys SAS
Estimated · fresh NCT07326540
Unlock 5 more readouts with confidence-graded estimates
Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Lower Respiratory Tract Infection Treatments by Mechanism

Top 4 mechanisms across 7 industry trials with a known mechanism of action.

See full pipeline →
Tetracycline-class Antibacterial
3 trials 2 sponsors
Fluoroquinolone Antibacterial
2 trials 2 sponsors
Interleukin-1 Receptor Antagonist
1 trials 1 sponsor
Interleukin-6 Antagonist
1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Lower Respiratory Tract Infection Clinical Pipeline by Phase

230 industry-sponsored trials across 125 sponsors

Novel Lower Respiratory Tract Infection Drugs by Company (New molecular entities)

No novel drugs found for this indication.

Reformulations (11 drugs) Click to expand

Lower Respiratory Tract Infection Drug Targets

Molecular targets of approved and investigational Lower Respiratory Tract Infection drugs — 1 target tracked.

Generic Drugs (17 ANDA approved) Click to expand

Drug Categories:

  • Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
  • Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
  • Biosimilars: BLA-approved biologics highly similar to reference products
  • Generics: ANDA-approved copies of small molecule drugs

View data sources and methodology